Online inquiry

IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9515MR)

This product GTTS-WQ9515MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLH1 gene. The antibody can be applied in Prostate Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2346
UniProt ID Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9515MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14673MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ15299MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ4710MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ11208MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ12080MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ1975MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ14010MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ5502MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP 6038
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW